Fund
ETHSX
Price as of:
$12.26
- $0.21
- 1.68%
Primary Theme
fund company
Name
As of 06/01/2026Price
Aum/Mkt Cap
YIELD
Annualized forward dividend yield. Multiplies the most recent dividend payout amount by its frequency and divides by the previous close price.
Exp Ratio
Expense ratio is the fund’s total annual operating expenses, including management fees, distribution fees, and other expenses, expressed as a percentage of average net assets.
Watchlist
Vitals
YTD Return
-7.7%
1 yr return
3.7%
3 Yr Avg Return
3.1%
5 Yr Avg Return
3.2%
Net Assets
$763 M
Holdings in Top 10
55.7%
52 WEEK LOW AND HIGH
$12.5
N/A
N/A
Expenses
OPERATING FEES
Expense Ratio 1.21%
SALES FEES
Front Load 5.25%
Deferred Load N/A
TRADING FEES
Turnover 32.00%
Redemption Fee N/A
Min Investment
Standard (Taxable)
$1,000
IRA
N/A
Fund Classification
Fund Type
Open End Mutual Fund
Name
As of 06/01/2026Price
Aum/Mkt Cap
YIELD
Annualized forward dividend yield. Multiplies the most recent dividend payout amount by its frequency and divides by the previous close price.
Exp Ratio
Expense ratio is the fund’s total annual operating expenses, including management fees, distribution fees, and other expenses, expressed as a percentage of average net assets.
Watchlist
ETHSX - Profile
Distributions
- YTD Total Return -7.7%
- 3 Yr Annualized Total Return 3.1%
- 5 Yr Annualized Total Return 3.2%
- Capital Gain Distribution Frequency Annually
- Net Income Ratio 0.30%
- Dividend Yield 0.6%
- Dividend Distribution Frequency None
Fund Details
-
Legal NameEaton Vance Worldwide Health Sciences Fund
-
Fund Family NameEaton Vance
-
Inception DateSep 11, 1996
-
Shares Outstanding57392692
-
Share ClassA
-
CurrencyUSD
-
Domiciled CountryUS
-
ManagerJason Kritzer
Fund Description
The Fund normally invests at least 80% of its net assets (plus any borrowings for investment purposes) in securities (primarily common stocks) of companies principally engaged in the discovery, development, production or distribution of products (or services) related to scientific advances in health care, including biotechnology, pharmaceuticals, diagnostics, managed health care and medical equipment and supplies (“health sciences companies”) (the “80% Policy”). A company will be considered to be a health sciences company if, at the time of investment: (i) the company is classified as a member of the Global Industry Classification Standard (“GICS”) health care sector; (ii) the company is a component of the S&P 500 Health Care Index or the MSCI World Health Care Index; or (iii) 50% or more of the company’s sales, earnings or assets will arise from or will be dedicated to the application of scientific advances related to health care. The Fund invests in U.S. and foreign securities and will normally be invested in issuers located in and tied economically to at least three different countries. The Fund may invest in securities of both larger established and smaller emerging companies domiciled in developed or emerging markets, some of which may be denominated in foreign currencies or trade in the form of depositary receipts, such as American Depositary Receipts, which are either sponsored or unsponsored, and Global Depositary Receipts. The Fund has a policy of investing at least 25% of its assets in investments in the medical research and health care industry. Companies in the medical research and health care industry are categorized by GICS as pharmaceuticals, biotechnology, life sciences and health care equipment and services companies. The Fund may invest up to 5% of its total assets in royalty bonds, which are debt securities that are collateralized by royalties from pharmaceutical patents. The Fund may also invest in exchange-traded funds (“ETFs”), a type of pooled investment vehicle, in order to manage cash positions or seek exposure to certain markets or market sectors and may lend its securities.
The Fund may engage in derivative transactions to seek return, to hedge against fluctuations in securities prices or currency exchange rates, or as a substitute for the purchase or sale of securities or currencies. The Fund expects to use derivatives primarily to seek to generate income by writing covered call options or put options. The Fund may also enter into a combination of option transactions on individual securities. In addition, the Fund may seek to hedge against fluctuations in currency exchange rates through the use of forward foreign currency exchange contracts. Permitted derivatives include: the purchase or sale of forward or futures contracts; options on futures contracts; exchange-traded and over-the-counter options; equity collars and equity swap agreements. The Fund may also engage in covered short sales (on individual securities held or on an index or basket of securities whose constituents are held in whole or in part or for which liquid assets have been segregated). Except as required by applicable regulation, there is no stated limit on the Fund’s use of derivatives for such purposes.
Investment decisions are made primarily on the basis of fundamental research. The portfolio managers seek to purchase stocks that are reasonably priced in relation to their fundamental value, and that they believe will grow in value over time regardless of short-term market fluctuations. In making investment decisions, the portfolio managers utilize the information provided by, and the expertise of, the investment adviser’s and sub-adviser’s research staff. In selecting stocks, the portfolio managers consider (among other factors) a company’s earnings or cash flow capabilities, dividend prospects, financial strength, growth potential, the strength of the company’s business franchises and management team, sustainability of a company’s competitiveness, estimates of the company’s net value, the potential to increase market share (for larger companies), and the potential of research and development projects (for smaller companies). The portfolio managers may consider selling a holding whenever there is a fundamental change to the investment thesis, the investment’s valuation target is reached, a security’s price falls below acquisition cost or to pursue more attractive investment opportunities. The portfolio managers seek to manage investment risk by maintaining issuer diversification among the Fund’s holdings, and by conducting an analysis of the risk and return characteristics of securities (as described above) in which the Fund invests.
ETHSX - Performance
Return Ranking - Trailing
| Period | ETHSX Return | Category Return Low | Category Return High | Rank in Category (%) |
|---|---|---|---|---|
| YTD | -7.7% | -22.9% | 20.0% | 90.63% |
| 1 Yr | 3.7% | -20.4% | 134.5% | 94.38% |
| 3 Yr | 3.1%* | -6.3% | 23.9% | 82.50% |
| 5 Yr | 3.2%* | -15.5% | 12.3% | 58.06% |
| 10 Yr | 6.7%* | 3.0% | 13.1% | 76.38% |
* Annualized
Return Ranking - Calendar
| Period | ETHSX Return | Category Return Low | Category Return High | Rank in Category (%) |
|---|---|---|---|---|
| 2025 | 2.6% | -21.9% | 61.0% | 90.00% |
| 2024 | -1.0% | -28.2% | 19.2% | 40.00% |
| 2023 | 3.0% | -8.6% | 19.0% | 49.38% |
| 2022 | -13.2% | -53.9% | 3.2% | 58.71% |
| 2021 | 12.3% | -39.6% | 24.2% | 16.77% |
Total Return Ranking - Trailing
| Period | ETHSX Return | Category Return Low | Category Return High | Rank in Category (%) |
|---|---|---|---|---|
| YTD | -7.7% | -22.9% | 20.0% | 90.63% |
| 1 Yr | 3.7% | -20.4% | 134.5% | 94.38% |
| 3 Yr | 3.1%* | -6.3% | 23.9% | 82.50% |
| 5 Yr | 3.2%* | -15.5% | 12.3% | 58.06% |
| 10 Yr | 6.7%* | 3.0% | 13.1% | 76.38% |
* Annualized
Total Return Ranking - Calendar
| Period | ETHSX Return | Category Return Low | Category Return High | Rank in Category (%) |
|---|---|---|---|---|
| 2025 | 10.3% | -0.5% | 63.7% | 84.38% |
| 2024 | 3.5% | -28.2% | 19.2% | 42.50% |
| 2023 | 5.7% | -8.6% | 19.0% | 35.63% |
| 2022 | -9.4% | -53.9% | 3.7% | 43.23% |
| 2021 | 22.1% | -33.9% | 26.0% | 7.10% |
NAV & Total Return History
ETHSX - Holdings
Concentration Analysis
| ETHSX | Category Low | Category High | ETHSX % Rank | |
|---|---|---|---|---|
| Net Assets | 763 M | 6.38 M | 37.9 B | 45.00% |
| Number of Holdings | 44 | 24 | 416 | 88.13% |
| Net Assets in Top 10 | 478 M | 3.49 M | 22.8 B | 40.00% |
| Weighting of Top 10 | 55.72% | 16.2% | 79.4% | 13.75% |
Top 10 Holdings
- Eli Lilly Co 11.33%
- AbbVie Inc 6.66%
- AstraZeneca PLC 6.54%
- Johnson Johnson 6.28%
- Roche Holding AG 5.85%
- Merck Co Inc 4.43%
- Bristol-Myers Squibb Co 4.10%
- UnitedHealth Group Inc 3.74%
- Vertex Pharmaceuticals Inc 3.51%
- Gilead Sciences Inc 3.27%
Asset Allocation
| Weighting | Return Low | Return High | ETHSX % Rank | |
|---|---|---|---|---|
| Stocks | 99.67% | 88.27% | 106.13% | 24.38% |
| Cash | 0.33% | 0.00% | 32.31% | 83.13% |
| Preferred Stocks | 0.00% | 0.00% | 7.86% | 33.75% |
| Other | 0.00% | -22.99% | 4.13% | 34.38% |
| Convertible Bonds | 0.00% | 0.00% | 0.37% | 7.74% |
| Bonds | 0.00% | 0.00% | 12.39% | 18.13% |
Stock Sector Breakdown
| Weighting | Return Low | Return High | ETHSX % Rank | |
|---|---|---|---|---|
| Healthcare | 100.00% | 59.26% | 100.00% | 0.65% |
| Utilities | 0.00% | 0.00% | 0.00% | 0.65% |
| Technology | 0.00% | 0.00% | 22.69% | 7.74% |
| Real Estate | 0.00% | 0.00% | 5.89% | 5.81% |
| Industrials | 0.00% | 0.00% | 7.02% | 7.10% |
| Financial Services | 0.00% | 0.00% | 1.60% | 29.03% |
| Energy | 0.00% | 0.00% | 0.00% | 0.65% |
| Communication Services | 0.00% | 0.00% | 9.11% | 3.87% |
| Consumer Defense | 0.00% | 0.00% | 25.73% | 10.97% |
| Consumer Cyclical | 0.00% | 0.00% | 1.92% | 7.10% |
| Basic Materials | 0.00% | 0.00% | 7.16% | 33.55% |
Stock Geographic Breakdown
| Weighting | Return Low | Return High | ETHSX % Rank | |
|---|---|---|---|---|
| US | 75.24% | 60.50% | 104.41% | 92.50% |
| Non US | 24.43% | 0.00% | 36.86% | 7.50% |
ETHSX - Expenses
Operational Fees
| ETHSX Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
|---|---|---|---|---|
| Expense Ratio | 1.21% | 0.08% | 4.69% | 44.38% |
| Management Fee | 0.80% | 0.03% | 1.25% | 64.38% |
| 12b-1 Fee | 0.25% | 0.00% | 1.00% | 21.33% |
| Administrative Fee | 0.15% | 0.03% | 0.25% | 47.22% |
Sales Fees
| ETHSX Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
|---|---|---|---|---|
| Front Load | 5.25% | 3.50% | 5.75% | 70.83% |
| Deferred Load | N/A | 1.00% | 1.00% | N/A |
Trading Fees
| ETHSX Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
|---|---|---|---|---|
| Max Redemption Fee | N/A | 1.00% | 1.00% | N/A |
Related Fees
Turnover provides investors a proxy for the trading fees incurred by mutual fund managers who frequently adjust position allocations. Higher turnover means higher trading fees.
| ETHSX Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
|---|---|---|---|---|
| Turnover | 32.00% | 1.00% | 238.00% | 23.19% |
ETHSX - Distributions
Dividend Yield Analysis
| ETHSX | Category Low | Category High | ETHSX % Rank | |
|---|---|---|---|---|
| Dividend Yield | 0.58% | 0.00% | 6.24% | 15.00% |
Dividend Distribution Analysis
| ETHSX | Category Low | Category High | Category Mod | |
|---|---|---|---|---|
| Dividend Distribution Frequency | None | Annual | Annual | Annual |
Net Income Ratio Analysis
| ETHSX | Category Low | Category High | ETHSX % Rank | |
|---|---|---|---|---|
| Net Income Ratio | 0.30% | -2.54% | 1.85% | 19.61% |
Capital Gain Distribution Analysis
| ETHSX | Category Low | Category High | Capital Mode | |
|---|---|---|---|---|
| Capital Gain Distribution Frequency | Annually | Annually | Semi-Annually | Annually |
Distributions History
| Date | Amount | Type |
|---|---|---|
| Dec 04, 2025 | $0.073 | OrdinaryDividend |
| Dec 04, 2025 | $0.019 | CapitalGainShortTerm |
| Dec 04, 2025 | $0.886 | CapitalGainLongTerm |
| Dec 05, 2024 | $0.024 | OrdinaryDividend |
| Dec 05, 2024 | $0.599 | CapitalGainLongTerm |
| Dec 05, 2024 | $0.623 | OrdinaryDividend |
| Dec 07, 2023 | $0.017 | OrdinaryDividend |
| Dec 07, 2023 | $0.308 | CapitalGainLongTerm |
| Dec 08, 2022 | $0.562 | OrdinaryDividend |
| Dec 09, 2021 | $1.206 | OrdinaryDividend |
| Dec 10, 2020 | $0.955 | OrdinaryDividend |
| Dec 03, 2019 | $0.667 | OrdinaryDividend |
| Dec 04, 2018 | $0.109 | CapitalGainShortTerm |
| Dec 04, 2018 | $0.428 | CapitalGainLongTerm |
| Dec 04, 2018 | $0.035 | OrdinaryDividend |
| Dec 21, 2017 | $0.291 | CapitalGainLongTerm |
| Dec 13, 2016 | $1.161 | CapitalGainLongTerm |
| Dec 15, 2015 | $0.153 | CapitalGainShortTerm |
| Dec 15, 2015 | $1.018 | CapitalGainLongTerm |
| Dec 16, 2014 | $0.565 | CapitalGainShortTerm |
| Dec 16, 2014 | $1.453 | CapitalGainLongTerm |
| Dec 17, 2013 | $0.198 | CapitalGainShortTerm |
| Dec 17, 2013 | $1.167 | CapitalGainLongTerm |
| Dec 17, 2013 | $0.069 | OrdinaryDividend |
| Dec 20, 2012 | $0.540 | CapitalGainShortTerm |
| Dec 20, 2012 | $0.701 | CapitalGainLongTerm |
| Dec 20, 2012 | $0.231 | OrdinaryDividend |
| Dec 28, 2011 | $0.904 | CapitalGainLongTerm |
| Dec 29, 2010 | $0.610 | CapitalGainLongTerm |
| Dec 30, 2009 | $0.007 | CapitalGainLongTerm |
| Dec 23, 2008 | $0.248 | CapitalGainShortTerm |
| Dec 23, 2008 | $1.098 | CapitalGainLongTerm |
| Dec 24, 2007 | $1.800 | CapitalGainLongTerm |
| Dec 20, 2006 | $0.171 | CapitalGainLongTerm |
| Sep 20, 2001 | $0.450 | CapitalGainLongTerm |
| Dec 13, 2000 | $0.046 | CapitalGainShortTerm |
| Oct 02, 2000 | $1.390 | CapitalGainLongTerm |
| Dec 15, 1999 | $0.277 | CapitalGainLongTerm |
| Oct 04, 1999 | $0.016 | CapitalGainShortTerm |
| Oct 04, 1999 | $1.130 | CapitalGainLongTerm |
| Dec 22, 1998 | $0.069 | CapitalGainShortTerm |
| Dec 22, 1998 | $0.603 | CapitalGainLongTerm |
ETHSX - Fund Manager Analysis
Managers
Jason Kritzer
Start Date
Tenure
Tenure Rank
Jul 01, 2016
5.92
5.9%
Mr. Kritzer is a Vice President of Eaton Vance. Prior to joining Eaton Vance in 2012, Mr. Kritzer was a director and equity analyst at BlackRock , Inc. covering the healthcare sector since 2006.
Samantha Pandolfi
Start Date
Tenure
Tenure Rank
Jul 01, 2016
5.92
5.9%
Ms. Pandolfi is a Vice President of EVAIL. Prior to joining EVAIL, Ms. Pandolfi held similar positions at EVMI. Prior to joining EVMI as a Vice President in November 2015, Ms. Pandolfi was a Portfolio Manager and Research Analyst with Goldman Sachs Asset Management over her fifteen year tenure (2000-2015).
Tenure Analysis
| Category Low | Category High | Category Average | Category Mode |
|---|---|---|---|
| 0.02 | 24.72 | 8.08 | 0.25 |